HLA class II histocompatibility antigen, DRB1-18 beta chain (HLA-DRB1*18)

The HLA class II histocompatibility antigen, DRB1-18 beta chain is a polymorphic protein component of the Major Histocompatibility Complex (MHC) class II receptor system [1]. It pairs with an alpha chain (HLA-DRA) to form the functional HLA-DR heterodimer, which is expressed primarily on the surface of professional antigen-presenting cells such as B cells, macrophages, and dendritic cells [2]. Its fundamental biological function involves the binding and presentation of exogenous peptides to CD4+ T-cell receptors, a process critical for the initiation of the adaptive immune response and the maintenance of self-tolerance [1]. The DRB1*18 allele group is specifically recognized for its clinical associations with autoimmune disorders, including systemic lupus erythematosus (SLE) and certain forms of inflammatory arthritis, where it may present self-peptides that trigger aberrant immune activation [3]. In drug discovery, this molecule is a focal point for developing peptide-based vaccines and immunomodulators designed to competitively occupy the peptide-binding groove or alter T-cell signaling [4]. Therapeutic strategies targeting HLA-DRB1*18 aim to achieve precise immune regulation, particularly in patients where this specific allele drives disease pathogenesis [3, 4].

Other names

HLA-DRB1*18MHC class II antigen DRB1*18DR18Human leukocyte antigen DRB1*18HLA-DRB1*18:01

Competitive inhibition of the peptide-binding groove to prevent autoantigen presentation to CD4+ T-cells.